Which disease-modifying agents for multiple sclerosis (MS) (DMAMS) have been FDA-approved for use?

Updated: Oct 08, 2019
  • Author: Christopher Luzzio, MD; Chief Editor: Jasvinder Chawla, MD, MBA  more...
  • Print
Answer

Most of the disease-modifying agents for MS (DMAMS) have been approved for use only in relapsing forms of MS. However, siponimod, ocrelizumab, and cladribine are also approved for active secondary progressive disease. The DMAMS currently approved for use by the US Food and Drug Administration (FDA) include the following:

  • Interferon beta-1a (Avonex, Rebif) [6]
  • Interferon beta-1b (Betaseron, Extavia) [7]
  • Peginterferon beta-1a (Plegridy) [8]
  • Glatiramer acetate (Copaxone) [9]
  • Natalizumab (Tysabri) [10, 11]
  • Mitoxantrone [12]
  • Fingolimod (Gilenya) [13]
  • Siponimod (Mayzent) [14]
  • Teriflunomide (Aubagio) [15]
  • Dimethyl fumarate (Tecfidera) [16, 17, 18, 19]
  • Alemtuzumab (Lemtrada) [20, 21, 22]
  • Daclizumab (Zinbryta) [23, 24]
  • Ocrelizumab (Ocrevus) [23, 24]
  • Cladribine (Mavenclad) [25, 26]

A single-use autoinjector is also available for self-injection of interferon beta-1a (Rebif) in patients with relapsing forms of MS. [27]


Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!